Sean Khozin: Mapping the temporal and epigenetic dimensions of tumor evolution
Sean Khozin, Chief Executive Officer at CEO Roundtable on Cancer, shared on X:
“The dynamic nature of cancer necessitates a shift from static to adaptive therapeutic strategies. A recent study on metastatic castration-resistant prostate cancer (mCRPC) exemplifies the need for such an approach by elucidating the epigenetic landscape evolution during disease progression.
Through chromatin accessibility profiling of 70 mCRPC tissue biopsies, researchers identified distinct accessibility patterns associated with androgen receptor functionality and delineated 203 transcription factors linked to mCRPC subtypes. Notably, the study highlighted ZNF263 as a potential key regulator in the double-negative subtype, possibly through MYC target activation.
This research not only provides insights into the epigenetic mechanisms underlying therapy resistance in mCRPC but also underscores the broader implications for cancer biology. By mapping the temporal and epigenetic dimensions of tumor evolution, such studies are giving us clues for developing more nuanced, temporally-aware therapeutic interventions across various cancer types.”
An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression
Autors: Raunak Shrestha, Lisa N. Chesner, Meng Zhang, Stanley Zhou, Adam Foye, Arian Lundberg, Alana S. Weinstein, Martin Sjöström, Xiaolin Zhu, Thaidy Moreno-Rodriguez, Haolong Li, SU2C/PCF West Coast Prostate Cancer Dream Team, Joshi J. Alumkal, Rahul Aggarwal, Eric J. Small, Mathieu Lupien, David A. Quigley, Felix Y. Feng
Source: Sean Khozin/X